Making Good Medicines Even Better

There are thousands of good medicines that help patients in many ways. But some medicines could be better. They might have unwanted side-effects, burdensome dosing regimens, difficult routes of administration or could even have new uses.
Making Good Medicines Even Better

Innovation Around Existing Molecules

We believe we can make some medicines even better through a pioneering new approach, which aims to create novel new treatments and treatment modalities, based on existing molecules. We call these potential new medicines New Therapeutic Entities (NTEs).

With the vision of bringing added value to patients, doctors and healthcare systems, Teva has created an industry-leading process that leverages our unique competitive advantage – the integration of our generics and specialty R&D capabilities – in the development of new treatments.

This vision has led to a new reality - the groundbreaking creation of a whole new pharmaceutical model.

What is Innovation Around Existing Molecules?

Innovation around existing molecules is all about developing new specialty medicines (NTEs) based on known and approved chemical molecules. These molecules are reformulated, repurposed or re-engineered to be delivered in a new way to address specific, unmet patient needs.

Teva is doing this in an unprecedented way. We are the first company to specifically focus on creating NTEs on an industrialized scale. 

We have built a dedicated team and a specifically-designed process for the generation and assessment of potential NTE concepts. This recently initiated process has already delivered a range of potential new treatment options into various stages of development.

NTEs can benefit patients, clinicians and payors. These new drugs can offer improvements such as better efficacy, increased adherence and improved compliance to treatment. Additionally, they offer the potential for fewer side effects and better quality of life as compared to the original formulation. NTEs may also reduce cost of treatment and financial burden to the healthcare system.

Since NTEs are based on known molecules with proven efficacy, they offer the possibility of getting improved medicines to patients faster. They are also likely to have higher development rate success compared to New Chemical Entities (NCEs).

Our NTE development programs include a range of abuse deterrent (AD) opioids for pain management and a once every 3 months regimen of an extended-release formulation of risperidone - an important drug used in the management of schizophrenia. 

NTE Case Study: A New Approach in Schizophrenia Management

Schizophrenia affects 24 million people. Antipsychotics are generally effective for the treatment of Schizophrenia, however there is a critical unmet need: 75% of patients are non-adherent to treatment within 2 years. Moreover, the relapse rate is 2-5 times higher in non-adherent patients. The economic burden of relapses and re-hospitalizations in US alone is $63B.

Long-acting Injectable antipsychotics improve adherence but have significant limitations. Risperidone is the most frequently prescribed atypical antipsychotic. Existing long-acting formulations require frequent clinic visits (every two weeks), intramuscular injections to the buttock, and must be prepared using 17 reconstitution steps.

Our current NTE LAI antipsychotic program is Risperidone LAI, which we are developing for delivery once every three months. This is based on an innovative proprietary technology that enables an extended-release of the medicine by means of a subcutaneous injection. We believe this will provide a product with the following characteristics:

  • Subcutaneous injection
  • Rapid onset of action
  • Minimal to no reconstitution steps
  • Decreased preparation time in office
  • Improved adherence